Curasight
12.60 DKK
+4.56 %
Less than 1K followers
CURAS
Spotlight Stock Market
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+4.56 %
+13.51 %
-6.67 %
+169.81 %
+322.82 %
+135.94 %
+82.85 %
-32.07 %
-9.70 %
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read moreMarket cap
603.83M DKK
Turnover
988.75K DKK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 2025-12-22
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26/2
2026
Annual report '25
23/4
2026
Interim report Q1'26
27/8
2026
Interim report Q2'26
All
Research
Webcasts
Press releases
ShowingAll content types
BioStock: Curasight reports encouraging preliminary data from uTREAT Phase I study
Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
